Shaia Jacqueline K, Rock Jenna R, Singh Rishi P, Talcott Katherine E, Cohen Devon A
Department of Population and Quantitative Health Sciences (JKS), Cleveland, Ohio; Case Western Reserve University, School of Medicine (JKS, JRR), Cleveland, Ohio; Center for Ophthalmic Bioinformatics (JKS, RPS, KET), Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University (RPS, KET), Cleveland Ohio; Cleveland Clinic Cole Eye Institute (RPS, KET, DAC), Cleveland, Ohio; and Cleveland Clinic Martin Hospitals (RPS), Cleveland Clinic Florida, Stuart, Florida.
J Neuroophthalmol. 2025 Jun 1;45(2):177-182. doi: 10.1097/WNO.0000000000002236. Epub 2024 Aug 16.
Tetracyclines and vitamin A derivatives, major components in acne care and antiaging products, have been associated with the development of drug-induced intracranial hypertension (DIIH). Treatment practices and longitudinal visual outcomes have been highly understudied in DIIH. The purpose of this study was to provide management guidelines for DIIH and report visual outcomes of patients with DIIH.
This was a single institute ophthalmology center case-control study where patients were seen between June 1, 2012, and September 1, 2023, in the United States. Patients with an International Classification of Disease (ICD) code for IIH and meeting the IIH diagnostic criteria who were taking a tetracycline or a vitamin A derivative during their diagnosis were included in this study. Patients were stratified into the following 3 categories: tetracyclines only, vitamin A derivatives only, or both, and compared with Kruskal-Wallis rank-sum tests. Poor visual outcomes were evaluated for and defined as a visual field mean deviation (peripheral visual measure) of -7 dB or greater. Individuals were followed for up to 1.5 years after diagnosis.
Among patients with IIH (n = 839), DIIH occurred in 8.10% of them (n = 68) with 83% taking the medication for acne. 88% of cases were female, and patients had a mean age of 24.96 years. DIIH medications were taken for an average length of 25.79 weeks before diagnosis of IIH. 20.5% of patients with DIIH were not treated with any IIH medication and were discontinued from the inducing drug. 3 patients had a poor visual outcome on follow-up with all of them taking a vitamin A derivative ( P < 0.05). Patients identified as having a poor visual outcome did not report discontinuing the DIIH drug ( P < 0.05).
We propose treatment guidelines highlighting that patients taking a DIIH medication who develop headaches or visual changes should be immediately referred to ophthalmology, removal of the offending agent, and close monitoring by ophthalmology for vision loss. Importantly, vitamin A DIIH may have more severe visual outcomes, but further research is needed to corroborate this finding.
四环素和维生素A衍生物是痤疮护理和抗衰老产品中的主要成分,与药物性颅内高压(DIIH)的发生有关。在DIIH中,治疗方法和纵向视觉结果的研究一直非常不足。本研究的目的是提供DIIH的管理指南,并报告DIIH患者的视觉结果。
这是一项单机构眼科中心的病例对照研究,研究对象为2012年6月1日至2023年9月1日期间在美国就诊的患者。患有国际疾病分类(ICD)编码的IIH且符合IIH诊断标准、在诊断期间正在服用四环素或维生素A衍生物的患者被纳入本研究。患者被分为以下3类:仅服用四环素、仅服用维生素A衍生物或两者都服用,并通过Kruskal-Wallis秩和检验进行比较。评估不良视觉结果并将其定义为视野平均偏差(周边视觉测量)为-7 dB或更低。个体在诊断后随访长达1.5年。
在IIH患者(n = 839)中,8.10%(n = 68)发生了DIIH,其中83%服用该药物治疗痤疮。88%的病例为女性,患者的平均年龄为24.96岁。在诊断IIH之前,DIIH药物的平均服用时长为25.79周。20.5%的DIIH患者未接受任何IIH药物治疗,且停用了诱发药物。3例患者在随访时出现不良视觉结果,他们均服用了维生素A衍生物(P < 0.05)。被确定为有不良视觉结果的患者未报告停用DIIH药物(P < 0.05)。
我们提出治疗指南,强调服用DIIH药物的患者若出现头痛或视觉变化,应立即转诊至眼科,停用致病药物,并由眼科密切监测视力丧失情况。重要的是,维生素A导致的DIIH可能会有更严重的视觉结果,但需要进一步研究来证实这一发现。